



PRODUCT: **Piqray® (alpelisib)**

COMPANY: Novartis Pharmaceuticals Corporation

THERAPEUTIC AREA & INDICATION:

Treatment of advanced or metastatic breast cancer  
with PIK3CA gene mutation

---

ABOUT THE PRODUCT

Approved in May 2019, PIQRAY was discovered at NIBR (Novartis Institutes for BioMedical Research) and was the first new drug application approved under the FDA Oncology Center of Excellence Real-Time Oncology Review pilot program. PIQRAY is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+/HER2-, PIK3CA-mutated, metastatic breast cancer, detected by an FDA-approved test following progression on or after an endocrine-based regimen. The first and only treatment specifically developed to target PI3Ka, PIQRAY delivers hope for patients facing aggressive disease and offers patients individualized therapy for their tumor harboring a PIK3CA mutation.